Compare Adaptive Biotechnologies Corp (ADPT) vs CVS Health Corp (CVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs CVS Health Corp — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B), while CVS Health Corp trades at $93.39 (market cap $119.58B). The key difference: CVS Health Corp is far larger — about 29.6× Adaptive Biotechnologies Corp's market cap, and CVS Health Corp pays a 2.84% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | CVS | |
|---|---|---|
Market Cap | $4.04B | $119.58B |
Sector | Health | Health |
52-Week High | $25.45 | $110.60 |
52-Week Low | $12.30 | $65.51 |
Enterprise Value | $4.10B | $181.93B |
Dividend Yield | — | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
CVS Health trades at $95.67, down slightly by 0.03% today. The stock shows strong fundamental momentum with recent quarterly earnings beats, including Q2 2026 EPS of $2.58 versus $1.87 expected, and raised 2026 guidance. Valuation metrics appear reasonable with a P/E of 24.67 and P/S of 0.29. Technical indicators are mixed with a bullish overall signal but bearish moving averages, with key support at $95 and resistance at $96.
The outlook for CVS is positive, supported by earnings strength and analyst consensus, but risks include margin pressure and rising debt levels. The consensus price target of $115.90 implies significant upside, though investors should monitor execution on guidance and healthcare regulatory changes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →
